Cellares Partners with Mitsui Fudosan for 2027 Launch of Regenerative Medicine Hub

• Cellares will establish its first Asian cell therapy manufacturing hub in Kashiwa-no-ha Smart City, Japan, set to open in 2027.

• The project is in collaboration with Mitsui Fudosan and located within the upcoming Mitsui Link Lab.

Cellares, in partnership with Mitsui Fudosan Co., Ltd., has announced plans to open its first Asian regenerative medicine manufacturing facility in Kashiwa-no-ha Smart City, Japan, by 2027.

The new site will be part of Mitsui Fudosan’s Mitsui Link Lab, currently under construction, and will serve as Cellares’ regional base for cell therapy production in Asia. Cellares, a U.S.-based company, is known for its contract manufacturing (CDMO) services for cell therapy medicines, including work for clients such as Bristol-Myers Squibb.

The expansion into Japan aims to address manufacturing and distribution bottlenecks that have hindered patient access to advanced therapies in the region. According to the companies, Japan’s current infrastructure challenges have contributed to delays in treatment availability and the absence of therapies already accessible in the U.S. and Europe.

Located in one of Japan’s designated bio-innovation hubs, the new facility is expected to enhance the ecosystem of Kashiwa-no-ha, which already hosts key players such as the National Cancer Center Hospital East.